therapeutic

FcRn is critical for IgG recycling and half-life extension. Biointron explores its biology and applications in designing durable therapeutic antibodies.

Bispecific antibody-drug conjugates (BsADCs) are a new class of therapeutic drugs being developed to fight cancer. They combine the dual targeting ability of bispecific antibodies with the cell-killing power of cytotoxic drugs. BsADCs are designed to deliver cytotoxic drugs directly to cancer cells, while minimizing damage to healthy cells. While they are still in development, several exciting advances have occurred recently.

Learn about bispecific antibodies (bsAbs), their history, advantages over monoclonal antibodies, and popular engineering formats like knobs-into-holes and BiTE.